Sign in

CIK 0001662774

  • Non-accelerated filer
  • Smaller reporting company

IRulya Therapeutics Inc.

Sign in to watch
Ticker
IRLA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
901024039
Phone
+1 203-208-8994
Business address
101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
Former names
Quince Therapeutics, Inc., Cortexyme, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Open-market buy Director bought 49,125 shares at an average $43.27 ($2,125,795)
  4. 4 Open-market sale 10% owner sold 370,000 shares at $40.18 ($14,866,600)
  5. 4 Exercise or conversion Chief Medical Officer acquired 5,515 shares (option exercise)
  6. 4 Open-market buy IA/Managing Member of 10% Owne bought 8,690 shares at an average $57.33 ($498,172)
  7. 4 Open-market buy Director bought 44,648 shares at an average $55.35 ($2,471,251)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 3 Insider Initial Statement of Ownership
  12. 4 Exercise or conversion Chief Medical Officer acquired 5,515 shares (option exercise)
  13. 4 Open-market buy Director bought 30,000 shares at $17.00 ($510,000)
  14. 4 Open-market buy Director bought 2,875 shares at $17.00 ($48,875)
  15. 4 Open-market buy Director bought 550 shares at $17.00 ($9,350)
  16. 4 Grant or award Director acquired 30,000 shares (grant or award)
  17. 4 Exercise or conversion Chief Medical Officer acquired 17,231 shares (option exercise)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 9 of 11 · 211 filings